Segui
Jenny sprooten
Jenny sprooten
Affiliazione sconosciuta
Email verificata su sprooten.nl
Titolo
Citata da
Citata da
Anno
Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity
L Vanderbeke, P Van Mol, Y Van Herck, F De Smet, S Humblet-Baron, ...
Nature communications 12 (1), 4117, 2021
2032021
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
I Vanmeerbeek, J Sprooten, D De Ruysscher, S Tejpar, P Vandenberghe, ...
Oncoimmunology 9 (1), 1703449, 2020
1912020
Trial watch: dendritic cell vaccination for cancer immunotherapy
J Sprooten, J Ceusters, A Coosemans, P Agostinis, S De Vleeschouwer, ...
Oncoimmunology 8 (11), 1638212, 2019
1322019
Necroptosis in immuno-oncology and cancer immunotherapy
J Sprooten, P De Wijngaert, I Vanmeerbeek, S Martin, P Vangheluwe, ...
Cells 9 (8), 1823, 2020
1132020
Type I interferons and dendritic cells in cancer immunotherapy
J Sprooten, P Agostinis, AD Garg
International Review of Cell and Molecular Biology 348, 217-262, 2019
982019
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer
RS Laureano, J Sprooten, I Vanmeerbeerk, DM Borras, J Govaerts, ...
Oncoimmunology 11 (1), 2096363, 2022
642022
Type I interferons and endoplasmic reticulum stress in health and disease
J Sprooten, AD Garg
International review of cell and molecular biology 350, 63-118, 2020
642020
Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer
J Sprooten, A Vankerckhoven, I Vanmeerbeek, DM Borras, Y Berckmans, ...
Journal for Immunotherapy of Cancer 9 (11), 2021
282021
Identification of potential prognostic and predictive immunological biomarkers in patients with stage I and stage III non-small cell lung cancer (NSCLC): a prospective …
RDW Vaes, K Reynders, J Sprooten, KT Nevola, KMA Rouschop, ...
Cancers 13 (24), 6259, 2021
202021
Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy
I Vanmeerbeek, DM Borras, J Sprooten, O Bechter, S Tejpar, AD Garg
Genes & Immunity 22 (2), 108-119, 2021
202021
Multiomics and spatial mapping characterizes human CD8+ T cell states in cancer
S Naulaerts, A Datsi, DM Borras, A Antoranz Martinez, J Messiaen, ...
Science Translational Medicine 15 (691), eadd1016, 2023
182023
Trial watch: chemotherapy-induced immunogenic cell death in oncology
J Sprooten, RS Laureano, I Vanmeerbeek, J Govaerts, S Naulaerts, ...
Oncoimmunology 12 (1), 2219591, 2023
172023
The interface of tumour-associated macrophages with dying cancer cells in immuno-oncology
I Vanmeerbeek, J Govaerts, RS Laureano, J Sprooten, S Naulaerts, ...
Cells 11 (23), 3890, 2022
112022
Single cell dynamics of tumor specificity vs bystander activity in CD8+ T cells define the diverse immune landscapes in colorectal cancer
DM Borràs, S Verbandt, M Ausserhofer, G Sturm, J Lim, GA Verge, ...
Cell Discovery 9 (1), 114, 2023
92023
Immunogenomic, single-cell and spatial dissection of CD8+T cell exhaustion reveals critical determinants of cancer immunotherapy
S Naulaerts, DM Borras, AA Martinez, J Messiaen, Y Van Herck, L Gelens, ...
BioRxiv, 2021.11. 22.468617, 2021
72021
A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology
J Sprooten, A Coosemans, AD Garg
Oncoimmunology 11 (1), 2024692, 2022
52022
A lymph node-to-tumour PDL1+macrophage circuit antagonizes dendritic cell immunotherapy
J Sprooten, I Vanmeerbeek, A Datsi, J Govaerts, DM Borràs, S Naulaerts, ...
bioRxiv, 2023.03. 14.532534, 2023
22023
Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells
J Sprooten, I Vanmeerbeek, A Datsi, J Govaerts, S Naulaerts, ...
Cell Reports Medicine 5 (1), 2024
12024
The cell stress and immunity cycle in cancer: Toward next generation of cancer immunotherapy
RS Laureano, I Vanmeerbeek, J Sprooten, J Govaerts, S Naulaerts, ...
Immunological Reviews 321 (1), 71-93, 2024
12024
77P Identification of prognostic and predictive immunological biomarkers in stage I and III non-small cell lung cancer (NSCLC) patients: A prospective exploratory study
R Vaes, K Reynders, J Sprooten, K Nevola, A Garg, M Lambrecht, ...
Annals of Oncology 32, S389, 2021
12021
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20